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Introduction
Meningiomas are an extremely common form of central ner-
vous system tumour. Arising from the arachnoidal cells of the
meninges,1–3 meningiomas are predominantly benign, al-
though in up to 10% of cases, they may show overt signs of
malignancy such as nuclear pleomorphism, architectural
disorganization, necrosis, prominent nucleoli and increased
mitosis.4 The often critical location of meningiomas may
make complete resection difficult, often leading to rapid re-
currence.5 While meningiomas make up approximately 20% of
central nervous system tumours in Western populations,6,7
they can represent up to 35% of central nervous system tu-
mours in Asian and African populations.8–10 As yet, it is un-
clear why meningiomas are more common in Asian popula-
tions; significant differences in tumour aetiology between
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meningiomas from Western cohorts and those from studies in
Asia have not been documented.
Mutations in the p53 tumour suppressor gene are present
in many different tumours, often at a high rate.11 Such muta-
tions often lead to over-expression of the p53 protein, as
detected by immunohistochemistry, due to stabilization of
the mutant protein and, therefore, p53 over-expression is
often used as a marker for p53 point mutation.
Many studies have examined benign and atypical/malig-
nant meningiomas for over-expression of the p53 protein with
diverse results:12–24 p53 over-expression has been reported in
0–10% of benign, 50–72.7% of atypical and 77–88.9% of ana-
plastic or malignant meningiomas.10,19,22,23 Despite the differ-
ing rates, all of the studies are consistent, with atypical/malig-
nant tumours showing higher rates of over-expression than
benign meningiomas. However, studies on the biological sig-
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nificance of p53 over-expression are highly contradictory.
While over-expression of p53 has been associated with recur-
rence in some studies,14,15,19 no association has been found in
others,13,18,24 and still other studies have suggested that ex-
pression of high levels of p53 may be protective against
recurrence.25
Fewer studies, however, have examined the p53 gene di-
rectly for mutations,19–23,26–28 and these studies typically have
not observed mutations in the p53 gene,19–21,26–28 although
rare mutants have been described.22,27 One group working on
specimens from Korean patients has documented a rate of
nearly 40% of p53 over-expressing meningiomas as having
mutations, and observed that the mutation rate was associ-
ated with both histological grade and recurrence.23 In light of
the high rate of p53 mutants documented in Asian patients
in the Korean study, we sought to determine whether well-
characterized meningiomas from our earlier series10,24 also
showed evidence of high levels of mutations in the p53 gene.
Materials and methods
Patients and tumours
Meningioma samples were selected from two previously ana-
lysed series of meningiomas.10,24 The first of these series con-
sisted of 20 benign and 20 malignant meningiomas examined
for p53 and bax over-expression as well as for the presence of
apoptotic cells,10 while the second series consisted of 90 be-
nign meningiomas examined for over-expression of p53, mdm2
and the progesterone receptor.24 A total of 27 samples were
selected, 19 benign meningiomas and eight malignant menin-
giomas. All 19 benign meningiomas stained positive for p53
over-expression (12 with positive nuclear expression and 7
with cytoplasmic staining); they came from 13 male patients
aged 44–75 years and six female patients aged 39–69 years. Of
the eight malignant meningiomas, three had positive nuclear
staining and five were negative for p53 over-expression; they
came from three males aged 51–78 years and five female
patients aged 28–79 years. The whole cohort consisted of 16
male and 11 female patients.
p53 mutation analysis
Genomic DNA was prepared from one 10 +m thick section
of paraffin-embedded tissue from each selected tumour. The
tissue section was placed in a 1.5 mL centrifuge tube together
with 1 mL of xylene and incubated in a tube rotator for 30
minutes at room temperature. The contents were subsequently
pelleted by centrifugation. Two further resuspension and
pelleting steps were undertaken. The pellet was washed twice
with absolute ethanol, air dried, resuspended in 100 +L water
containing 20 mg proteinase K (Boehringer Mannheim GmBH,
Penzburg, Germany) and 5% sodium dodecylsulfate and incu-
bated overnight at 50$C. Proteinase K was inactivated by
heating to 90$C and the debris was pelleted by centrifugation.
The supernatant was extracted twice with an equal volume of
phenol and once with chloroform. DNA was precipitated by
addition of 2.5 volumes ice-cold ethanol and sodium acetate
to 0.3 M and incubating at –80$C for 15 minutes. The DNA
was pelleted by centrifugation and resuspended in sterile
distilled water.
Exons 4 to 9, inclusive, of the p53 gene were amplified
separately by polymerase chain reaction (PCR) using specific
primer pairs (Table). The amplification products were puri-
fied by agarose gel electrophoresis and excised from the gel
matrix, after which templates were purified using the Geneclean
III Kit (Bio101, Vista, CA, USA) and subjected directly to DNA
sequence analysis. DNA sequencing reactions were performed
using the Big Dye Termination Reaction Kit (PE Applied
Biosystems, Foster City, CA, USA) on approximately 60–90 ng
of purified template. Analysis was undertaken on an auto-
mated ABI 377-18 DNA sequencer (PE Applied Biosystems).
Table. Primer pairs
Exon Size (bp) Forward primer Reverse primer
4 460 5'-AAGGACAAGGGTTGGGC-3' 5'-AGGAATCCCAAAGTTCCA-3'
5 264 5'-TTGTGCCCTGACTTTCAA-3' 5'-AACCAGCCCTGTCGTCTCT-3'
6 217 5'-AGACGACAGGGCTGGTT-3' 5'-ACCCTTAACCCCTCCTC-3'
7 232 5'-TTGCCACAGGTCTCCCCAA-3' 5'-GTCAGAGGCAAGCAGA-3'
8 344 5'-TGGTTGGGAGTAGATGGA-3' 5'-AGGAAAGAGGCAAGGAAA-3'
9 275 5'-AGCACTAAGCGAGGTAA-3' 5'-TGCCCCAATTGCAGGTAAA-3'
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Results
A single transition mutation was detected in exon 6 at codon
223 (CCG to CTG) in a sample from a benign meningioma
with nuclear p53 over-expression (Figure). This mutation
changed the encoded proline to a leucine (Pro223Leu).
Discussion
Our detection of a single mutation in a benign meningioma
contrasts sharply with the results of Cho et al, who docu-
mented p53 mutations in up to 40% of Korean patients,23 but
is more in accord with those of other studies.19–22,26–28 The
discrepancy between our study and that of Cho et al is unlikely
to arise from the extent of the p53 gene investigated, as while
Cho et al studied exons 5 to 8,23 our study examined exons 4 to
9 inclusive, a region known to contain the vast majority of all
p53 mutations.29 One other study that has examined all p53
exons in meningioma cases also failed to find a high level of
mutation. While it is possible that our methodology of direct
sequencing of all exons failed to detect some mutants, the
single-strand conformational polymorphism pre-screening
methodology used by Cho and co-workers can also miss mu-
tants as the mutation may not introduce a large enough alter-
nate conformation.30 Several endogenous cellular mecha-
nisms have been proposed for the over-expression of p53 in the
absence of stabilizing mutations,31 but the primary cause of
p53 over-expression in meningiomas remains to be discovered.
Possible mechanisms include complexing with viral pro-
teins or the mdm2 protein,32 deletion of the INK4a-ARF
gene,33 cytoplasmic sequestration34 or even lesions in the
ubiquitination pathway that targets p53 for degradation.35 In
the absence of any evidence suggesting a viral aetiology for
meningiomas, it would seem likely that one of the latter
pathways may provide the reason for over-expression of p53 in
meningiomas without p53 mutations. Studies that have exam-
ined over-expression of the mdm2 protein provide little evi-
dence for a correlation between mdm2 over-expression and
p53 over-expression.19,24,36 Perhaps the most pressing ques-
tion at present is whether the over-expressed p53 in menin-
giomas retains some, or even all, of its function. Evidence
showing that the over-expressed p53 retains function sug-
gests that a critical molecular lesion lies further downstream
in the molecular pathway, possibly with one of the mediators
of cellular apoptosis,37 and we have started to investigate
proteins involved in the mediation of apoptosis in menin-
giomas.38
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